Security
BIOPHYTIS SA American Depositary Shares · BPTSY
BPTSYOTCotherCurrentCIK 1768946Updated Nov 3, 2026
BPTSY price & chart
Loading TradingView…
OTC:BPTSY on TradingView ↗About the company
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2023 · EURSource
Source
Source
cash flow · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossEUR | -17,026,000Source | -24,216,000Source | -31,164,000Source | -25,517,000Source |
| Cash flows from financing activities: | ||||
| Dividends paid | —Source | —Source | —Source | —Source |
| Additional Financial Items | ||||
| AdjustmentsForFinanceCostsEUR | 1,022,000Source | 1,853,000Source | 562,000Source | — |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableEUR | -1,328,000Source | -665,000Source | -380,000Source | -479,000Source |
| AdjustmentsForSharebasedPaymentsEUR | 812,000Source | 5,567,000Source | 3,422,000Source | 785,000Source |
| GeneralAndAdministrativeExpenseEUR | 5,488,000Source | 7,237,000Source | 7,150,000Source | 4,021,000Source |
| InterestPaidClassifiedAsFinancingActivitiesEUR | 460,000Source | 662,000Source | 562,000Source | 628,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | 283,000Source | 244,000Source | 54,000Source | — |
| ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssetsEUR | — | 14,000Source | 12,500,000Source | — |
| ProceedsFromIssuingSharesUSD | 3,800,000Source | — | 16,584,000Source | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | 220,000Source | 141,000Source | 344,000Source | 214,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | — | 1,844,000Source | — | — |
income statement · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.25Source | 0.25Source | 0.27Source | 0.28Source |
| AverageEffectiveTaxRatenumber | 0Source | 0Source | 0Source | 0Source |
| BasicEarningsLossPerShareEUR/shares | -0.03Source | -0.14Source | -0.26Source | -0.43Source |
| DilutedEarningsLossPerShareEUR/shares | -0.03Source | -0.14Source | -0.26Source | -0.43Source |
| EmployeeBenefitsExpenseEUR | — | 10,289,000Source | 7,499,000Source | 4,349,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | — | 5,567,000Source | 3,730,000Source | 785,000Source |
| FinanceCostsEUR | 1,633,000Source | 2,564,000Source | 2,517,000Source | 1,531,000Source |
| FinanceIncomeEUR | 269,000Source | 983,000Source | 24,000Source | 34,000Source |
| GeneralAndAdministrativeExpenseEUR | 5,488,000Source | 7,237,000Source | 7,150,000Source | 4,021,000Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillEUR | — | 0Source | 0Source | 0Source |
| OtherFinanceCostEUR | 157,000Source | 31,000Source | 166,000Source | 231,000Source |
| ProfitLossAttributableToNoncontrollingInterestsEUR | — | — | -1,000Source | — |
| ProfitLossAttributableToOwnersOfParentEUR | -17,026,000Source | -24,216,000Source | -31,163,000Source | -25,517,000Source |
| ProfitLossBeforeTaxEUR | -17,026,000Source | -24,216,000Source | -31,164,000Source | -25,517,000Source |
| ProfitLossFromOperatingActivitiesEUR | -14,333,000Source | -23,272,000Source | -26,815,000Source | -13,942,000Source |
| ResearchAndDevelopmentExpenseEUR | 8,845,000Source | 16,034,000Source | 19,665,000Source | 9,921,000Source |
Filing attachments
tm2628747d2_ex99-1.htm · 6-K · 2026-11-02
Exhibit 99.1 BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY Paris (France) and Cambridge (Massachusetts, United States), October 30, 2026 - 11.00 PM (CET) - Biophytis SA (Euronext Growth Paris : ALBPS), (“ Biophytis ” or the “ Company ”), a pioneer in the development of transformative therapies impacting longevity, reports its half-year financial results and provides an update on its strategic outlook. Stanislas Veillet, Chairman and CEO of Biophytis, state…
Read attachment ↗tm2625280d1_ex99-1.htm · 6-K · 2026-09-14
Exhibit 99.1 BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY Capital increase of €5.3 million in gross proceeds (€4.75 million cash and €0.55 million Hexagon debt roll) through the issuance of 101,923,092 new shares and warrants giving right to 127,403,865 new shares Obesity trial, through a combination of proceeds from the offering & existing credit lines, now fully funded to topline readout in half-year 2028 Placement bal…
Read attachment ↗tm2625095d1_ex99-1.htm · 6-K · 2026-09-09
Exhibit 99.1 Biophytis to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity Regulatory protocol amendment filed in Brazil, with submissions planned in the United States and Europe “Rebound effect”: expansion of the scope of BIO101 evaluation following semaglutide discontinuation A new follow-up phase to assess weight regain and the role of BIO101 Paris (France) and Cambridge (Massachusetts, U.S.), September 9, 2026, at 07:00am CET - Biophyti…
Read attachment ↗tm2624379d1_ex99-1.htm · 6-K · 2026-08-31
Exhibit 99.1 Biophytis strengthens its financial position and extends its cash runway into Q1 2027 Cash position strengthened to €3.0 million Most 2026 share warrants exercised Phase 2 study in obesity to start in Q1 2027 Hong-Kong JV to start operations for preparing Phase 3 study in sarcopenia Paris (France) and Cambridge (Massachusetts, U.S.), August 31, 2026, at 07:00am CET - Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a pioneering company …
Read attachment ↗tm2624101d1_ex99-1.htm · 6-K · 2026-08-26
Exhibit 99.1 BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE Paris (France) and Cambridge (Massachusetts, U.S.), August 03, 2026, at 07:00am CET - Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company pioneering the development of transformative therapies for longevity, provides an update on the rollout of its joint venture in Hong Kong (see details in the “About” section below) and shares its short-…
Read attachment ↗tm2621688d2_ex99-1.htm · 6-K · 2026-08-10
Exhibit 99.1 BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY Paris (France) and Cambridge (Massachusetts, U.S.), August 10, 2026, at 07:00am CET - Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company pioneering the development of transformative therapies for longevity, today announces that it has received approval from Brazil’s National Health Surveillance Agency (ANVISA) to begin the …
Read attachment ↗